₹
1054.00
May 3
Business Description
Glenmark Pharmaceuticals Ltd
ISIN : INE935A01035
Description
Financial Strength
5/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.26 | |||||
Equity-to-Asset | 0.47 | |||||
Debt-to-Equity | 0.56 | |||||
Debt-to-EBITDA | 7.14 | |||||
Interest Coverage | 2.74 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 2.78 | |||||
Beneish M-Score | -2.34 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 7 | |||||
3-Year EBITDA Growth Rate | -1.1 | |||||
3-Year EPS without NRI Growth Rate | 3.3 | |||||
3-Year FCF Growth Rate | -66.3 | |||||
3-Year Book Growth Rate | 16 | |||||
Future 3-5Y Total Revenue Growth Rate | -5.7 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.58 | |||||
9-Day RSI | 55.21 | |||||
14-Day RSI | 59.19 | |||||
6-1 Month Momentum % | 33.15 | |||||
12-1 Month Momentum % | 83.69 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 1.93 | |||||
Quick Ratio | 1.48 | |||||
Cash Ratio | 0.23 | |||||
Days Inventory | 197.21 | |||||
Days Sales Outstanding | 97.88 | |||||
Days Payable | 154.59 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.24 | |||||
Dividend Payout Ratio | 0.27 | |||||
3-Year Dividend Growth Rate | 7.7 | |||||
Forward Dividend Yield % | 0.24 | |||||
5-Year Yield-on-Cost % | 0.32 | |||||
Shareholder Yield % | -2.41 |
Profitability Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 60.33 | |||||
Operating Margin % | 9.9 | |||||
Net Margin % | -5.39 | |||||
FCF Margin % | 0.13 | |||||
ROE % | -7.52 | |||||
ROA % | -3.72 | |||||
ROIC % | 12.39 | |||||
ROC (Joel Greenblatt) % | 1.16 | |||||
ROCE % | 0.75 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio without NRI | 117.92 | |||||
Shiller PE Ratio | 34.34 | |||||
PEG Ratio | 47.17 | |||||
PS Ratio | 2.31 | |||||
PB Ratio | 3.27 | |||||
Price-to-Tangible-Book | 4.31 | |||||
Price-to-Free-Cash-Flow | 1728.08 | |||||
Price-to-Operating-Cash-Flow | 48.73 | |||||
EV-to-EBIT | 318.61 | |||||
EV-to-EBITDA | 46.27 | |||||
EV-to-Revenue | 2.55 | |||||
EV-to-FCF | 1946.19 | |||||
Price-to-Projected-FCF | 2.93 | |||||
Price-to-DCF (Earnings Based) | 11.95 | |||||
Price-to-DCF (FCF Based) | 181.72 | |||||
Price-to-Median-PS-Value | 1.29 | |||||
Price-to-Graham-Number | 2.66 | |||||
Price-to-Net-Current-Asset-Value | 50.62 | |||||
Earnings Yield (Greenblatt) % | 0.31 | |||||
FCF Yield % | 0.06 | |||||
Forward Rate of Return (Yacktman) % | 3.53 |